Chemoprevention Meets Glucose Control
Open Access
- 1 September 2010
- journal article
- editorial
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 3 (9), 1049-1052
- https://doi.org/10.1158/1940-6207.capr-10-0178
Abstract
The report by Memmott et al. (beginning on page 1066 in this issue of the journal) assessing the efficacy of the antidiabetes drug metformin in a mouse model of lung carcinogenesis suggests protective effects via two possible avenues: Decreased circulating insulin and insulin-like growth factor levels and energy stress leading to inhibition of mammalian target of rapamycin signaling. These potential mechanisms are discussed in this perspective, as are their implications for cancer prevention and therapy. Cancer Prev Res; 3(9); 1049–52. ©2010 AACR.Keywords
Other Versions
This publication has 29 references indexed in Scilit:
- Metformin and Other Biguanides in Oncology: Advancing the Research AgendaCancer Prevention Research, 2010
- Metformin Prevents Tobacco Carcinogen–Induced Lung TumorigenesisCancer Prevention Research, 2010
- Metformin, Independent of AMPK, Inhibits mTORC1 in a Rag GTPase-Dependent MannerCell Metabolism, 2010
- Intravesical Delivery of Rapamycin Suppresses Tumorigenesis in a Mouse Model of Progressive Bladder CancerCancer Prevention Research, 2009
- Rapamycin fed late in life extends lifespan in genetically heterogeneous miceNature, 2009
- Tumours with PI3K activation are resistant to dietary restrictionNature, 2009
- The TSC1–TSC2 complex: a molecular switchboard controlling cell growthBiochemical Journal, 2008
- AMPK Phosphorylation of Raptor Mediates a Metabolic CheckpointMolecular Cell, 2008
- Hypoxia regulates TSC1/2–mTOR signaling and tumor suppression through REDD1-mediated 14–3–3 shuttlingGenes & Development, 2008
- Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR ComplexScience, 2005